Products
Gefurulimab Biosimilar Bispecific Single-Domain Antibody (Complement C5 × Albumin) for Research
Cat No.: GMP-Bios-INN-1215
Anti-C5 therapeutic antibody (Pre-made Gefurulimab biosimilar,Bispecific Single Domains (VH-VH')) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Gefurulimab (development code ALXN1720) is a bispecific single-domain antibody targeting complement C5 and albumin. It is developed by Alexion Pharmaceuticals for myasthenia gravis and proteinuria. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1215-1mg | 1mg | |
| GMP-Bios-INN-1215-10mg | 10mg | |
| GMP-Bios-INN-1215-100mg | 100mg | |
| GMP-Bios-INN-1215-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Gefurulimab biosimilar, Bispecific Single Domains (VH-VH'), Anti-C5;ALB Antibody: Anti-C5/CO5/Complement C5/C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 therapeutic antibody |
| INN Name | Gefurulimab |
| Target | C5;ALB |
| Format | Bispecific Single Domains (VH-VH') |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na;na |
| VD LC | na;na |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None;8coh:A |
| 99% SI Structure | None;8coe:B |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Alexion Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Myasthenia gravis;Proteinuria |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
